康静波, 赵向飞, 聂青, 张丽萍, 朱奇, 李启亮, 王仁秋. 立体定向放疗联合热疗及索拉非尼治疗复发及转移性肝癌的疗效分析[J]. 中国肿瘤临床, 2013, 40(20): 1236-1239. DOI: 10.3969/j.issn.1000-8179.20131444
引用本文: 康静波, 赵向飞, 聂青, 张丽萍, 朱奇, 李启亮, 王仁秋. 立体定向放疗联合热疗及索拉非尼治疗复发及转移性肝癌的疗效分析[J]. 中国肿瘤临床, 2013, 40(20): 1236-1239. DOI: 10.3969/j.issn.1000-8179.20131444
shu
Jingbo KANG, Xiangfei ZHAO, Qing NIE, Liping ZHANG, Qi ZHU, Qiliang LI, Renqiu WANG. Efficacy of stereotactic body radiation therapy with γ-knife combined with hyperthermia and targeted drug sorafenib for the treatment of recurrent and metastatic hepatocellular carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 40(20): 1236-1239. DOI: 10.3969/j.issn.1000-8179.20131444
Citation: Jingbo KANG, Xiangfei ZHAO, Qing NIE, Liping ZHANG, Qi ZHU, Qiliang LI, Renqiu WANG. Efficacy of stereotactic body radiation therapy with γ-knife combined with hyperthermia and targeted drug sorafenib for the treatment of recurrent and metastatic hepatocellular carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 40(20): 1236-1239. DOI: 10.3969/j.issn.1000-8179.20131444
shu

立体定向放疗联合热疗及索拉非尼治疗复发及转移性肝癌的疗效分析

Efficacy of stereotactic body radiation therapy with γ-knife combined with hyperthermia and targeted drug sorafenib for the treatment of recurrent and metastatic hepatocellular carcinoma

    摘要
  • 摘要:
      目的  探讨γ-体部立体定向放疗（stereotactic body radiation therapy with γ-knife，γ-SBRT）联合热疗及靶向药物索拉非尼（sorafenib）治疗复发及转移性肝癌的效果。
      方法  自2007年8月至2009年12月，收治71例肝癌治疗后复发及转移患者。39例行γ-SBRT联合热疗，32例γ-SBRT联合热疗及索拉非尼治疗。
      结果  治疗后3个月总有效率为83.1%（59/71）。γ-SBRT+热疗组的1、3年局部控制率分别为41.0%（16/39）、18.0%（7/39））；γ-SBRT+热疗+索拉非尼组的1、3年局部控制率分别为56.3%（18/32）、28.1%（9/32）。γ-SBRT+热疗组的1、3年OS分别为41.2%（16/39）、17.9%（7/39），1、3年PFS分别为38.5%（15/39）、15.4%（6/39）；γ-SBRT+热疗+索拉非尼组的1、3年OS分别为62.5%（20/32）、28.1%（9/32），1、3年PFS分别为59.4%（19/32）、25.0%（9/32），经Log-rank检验两组的OS、PFS差异无显著性。
      结论  采用γ-SBRT联合热疗及索拉非尼对转移及复发性肝癌进行治疗是较有效的治疗方法。治疗过程安全，多数患者能耐受治疗。

     

    Abstract:
      Objective   To investigate the efficacy of stereotactic body radiation therapy with gamma-knife (γ-SBRT) combined with targeted drug sorafenib and hyperthermia for the treatment of recurrent and metastatic hepatocellular carcinoma.
      Methods   A total of 71 patients with recurrent and metastatic hepatocellular carcinoma were admitted from August 2007 to December 2009. Among these patients, 39 were treated with γ-SBRT and hyperthermia (group 1); 19 were treated with γ-SBRT combined with sorafenib and hyperthermia (group 2).
      Results   The total efficacy rate after a three-month treatment was 83.1% (59/71). In group 1, the following results were obtained: one- and three-year local control rates of 41.0% (16/39) and 18% (7/39), respectively; one- and three-year overall survival (OS) rates of 41.2% and 17.9%, respectively; and one- and three-year progression-free survival (PFS) rates of 38.4% and 15.4%, respectively. In group 2, the following results were obtained: one- and three-year local rates of 56.3% (18/32) and 28.1% (9/32), respectively; one- and three-year OS rates of 62.5% and 28.1%, respectively; and one- and three-year PFS rates of 59.4% and 25.0%, respectively. Significant differences in OS and PFS were observed between the two groups.
      Conclusion   The combination of γ-SBRT with targeted drug sorafenib and hyperthermia can be used effectively to treat recurrent and metastatic hepatocellular carcinoma. Adverse reactions are mild, and patients can tolerate this treatment.

     

    • HTML全文
    • 参考文献(12)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回